Surrozen(SRZNW)

Focus: Surrozen is a publicly traded biotech focused on Wnt signaling antibodies, a novel mechanism targeting tissue regeneration and repair. At 59 employees, it is a micro-cap biotech in early-stage development.

Profile data last refreshed 15h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

Open Jobs

About Surrozen

AI assessmentNot Hiring

No open roles listed right now. Follow Surrozen to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$11M

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

SEC Filings: 2 available

Financials (FY2025)

Help build intelligence for Surrozen

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline in an emerging mechanism (Wnt signaling) with potential to define a new therapeutic class
Public company status provides equity upside and regulatory transparency despite small headcount
Early-stage platform allows hands-on impact on core platform strategy and drug development decisions

Watch Out For

Severe cash burn ($63.6M net loss in FY2025 on $11M revenue) with only $35M cash, requiring financing or milestone-driven survival
Minimal hiring activity (0 active job openings) and skeleton crew (59 employees) signals minimal near-term growth and potential restructuring risk
No disclosed clinical programs, publications, or product data limits visibility into pipeline viability and technical depth

Generated by Claude from Surrozen's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

R&D Spend

$21M(198%)22%

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo